{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:23:20Z","timestamp":1791563000516,"version":"4.3.4"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T00:00:00Z","timestamp":1707177600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.radonc.2024.110147","type":"journal-article","created":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T00:45:02Z","timestamp":1707439502000},"page":"110147","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Diagnosis and management of pneumonitis following chemoradiotherapy and immunotherapy in stage III non-small cell lung cancer"],"prefix":"10.1016","volume":"194","author":[{"given":"I.","family":"Smesseim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.M.","family":"Mets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.A.","family":"Daniels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Bahce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Senan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2024.110147_b0005","doi-asserted-by":"crossref","DOI":"10.7573\/dic.212578","article-title":"Immunotherapy in inoperable stage III non-small cell lung cancer: a review","volume":"8","author":"Jain","year":"2019","journal-title":"Drugs Context"},{"key":"10.1016\/j.radonc.2024.110147_b0010","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.lungcan.2021.03.013","article-title":"Trends and variations in treatment of stage I-III non-small cell lung cancer from 2008 to 2018: a nationwide population-based study from the Netherlands","volume":"155","author":"Evers","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.radonc.2024.110147_b0015","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1200\/JCO.19.01162","article-title":"Long-Term results of NRG oncology RTOG 0617: standard- versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage III non-small-cell lung cancer","volume":"38","author":"Bradley","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2024.110147_b0020","first-page":"990","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer reply","volume":"380","author":"Antonia","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2024.110147_b0025","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2024.110147_b0030","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.21.02528","article-title":"Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline","volume":"40","author":"Daly","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2024.110147_b0035","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/annonc\/mdx222","article-title":"Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Postmus","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2024.110147_b0040","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0224-2020","article-title":"Developments in radiation techniques for thoracic malignancies","volume":"30","author":"Finazzi","year":"2021","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.radonc.2024.110147_b0045","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S1470-2045(14)71207-0","volume":"16","author":"Bradley","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2024.110147_b0050","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.lungcan.2022.06.005","article-title":"Chemoradiation-induced pneumonitis in patients with unresectable stage III non-small cell lung cancer: a systematic literature review and meta-analysis","volume":"174","author":"Kuang","year":"2022","journal-title":"Lung Cancer"},{"key":"10.1016\/j.radonc.2024.110147_b0055","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jtho.2022.10.003","article-title":"Treatment characteristics and real-world progression-free survival in patients with unresectable stage III NSCLC who received durvalumab after chemoradiotherapy: findings from the PACIFIC-R study","volume":"18","author":"Girard","year":"2023","journal-title":"J Thoracic Oncol: Official Publication Int Assoc Study Lung Cancer"},{"key":"10.1016\/j.radonc.2024.110147_b0060","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.jtho.2023.04.008","article-title":"Korean real-world data on patients with unresectable stage III NSCLC treated with durvalumab after chemoradiotherapy: PACIFIC-KR","volume":"18","author":"Park","year":"2023","journal-title":"J Thoracic Oncol: Official Publication Int Assoc Study Lung Cancer"},{"key":"10.1016\/j.radonc.2024.110147_b0065","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.radonc.2021.05.016","article-title":"Intensity-modulated radiation therapy with concurrent chemotherapy followed by durvalumab for stage III non-small cell lung cancer: a multi-center retrospective study","volume":"160","author":"Tsukita","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2024.110147_b0070","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s00408-022-00511-8","article-title":"Nationwide real-life safety and treatment exposure data on durvalumab after concurrent chemoradiotherapy in unresectable stage III, locally advanced, non-small cell lung cancer: analysis of patients enrolled in the french early access program","volume":"200","author":"Avrillon","year":"2022","journal-title":"Lung"},{"key":"10.1016\/j.radonc.2024.110147_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.clon.2023.07.003","article-title":"Pneumonitis after concurrent chemoradiation and immune checkpoint inhibition in patients with locally advanced non-small cell lung cancer","author":"Altan","year":"2023","journal-title":"Clin Oncol (Royal College of Radiologists)"},{"key":"10.1016\/j.radonc.2024.110147_b0080","doi-asserted-by":"crossref","first-page":"4238","DOI":"10.1038\/s41467-023-39874-8","article-title":"Impact of TMB\/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC","volume":"14","author":"Alessi","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.radonc.2024.110147_b0085","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.radonc.2017.11.003","article-title":"Long term radiological features of radiation-induced lung damage","volume":"126","author":"Veiga","year":"2018","journal-title":"Radiother Oncol"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814024000689?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814024000689?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T05:28:21Z","timestamp":1759123701000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814024000689"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":17,"alternative-id":["S0167814024000689"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2024.110147","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnosis and management of pneumonitis following chemoradiotherapy and immunotherapy in stage III non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2024.110147","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"110147"}}